keyword
MENU ▼
Read by QxMD icon Read
search

Hepatic arterial infusion chemotherapy

keyword
https://www.readbyqxmd.com/read/29234639/hepatocellular-carcinoma-with-macrovascular-invasion-defining-the-optimal-treatment-strategy
#1
REVIEW
Charlotte E Costentin, Cristina R Ferrone, Ronald S Arellano, Suvranu Ganguli, Theodore S Hong, Andrew X Zhu
Background: Tumoral macrovascular invasion (MVI) of hepatic and/or portal vein branches is a common phenomenon in hepatocellular carcinoma (HCC) and is associated with poorer prognosis when compared to HCC without MVI. Summary: Current international guidelines for the management of HCC recommend sorafenib as the only treatment option in case of MVI. Despite guideline recommendations, several alternative options have been tested to manage HCC with MVI: surgery, transarterial chemoembolization, external or internal radiation, hepatic arterial infusion chemotherapy, percutaneous treatment, cryotherapy, or the combination of two or more of these strategies, with or without sorafenib...
November 2017: Liver Cancer
https://www.readbyqxmd.com/read/29234631/sorafenib-versus-hepatic-arterial-infusion-chemotherapy-as-initial-treatment-for-hepatocellular-carcinoma-with-advanced-portal-vein-tumor-thrombosis
#2
Michihisa Moriguchi, Takeshi Aramaki, Hideyuki Nishiofuku, Rui Sato, Koiku Asakura, Kanji Yamaguchi, Toshihiro Tanaka, Masahiro Endo, Yoshito Itoh
Objective: To investigate the validity of hepatic arterial infusion chemotherapy with low-dose 5-fluorouracil and cisplatin (LFP) versus sorafenib as first-line treatment for hepatocellular carcinoma (HCC) with portal vein tumor thrombosis (Vp3, Vp4). Patients and Methods: We retrospectively reviewed the cases of Child-Pugh A advanced HCC with Vp3 or Vp4 treated with LFP or sorafenib between October 2002 and December 2013. Results: There were 32 patients in the LFP group and 14 patients in the sorafenib group...
November 2017: Liver Cancer
https://www.readbyqxmd.com/read/29233520/5-fu-or-mitomycin-c-hepatic-arterial-infusion-after-failure-of-arterial-oxaliplatin-in-patients-with-colorectal-cancer-unresectable-liver-metastases
#3
Simon Pernot, Guillaume Velut, Rapahel Hampig Kourie, Gregory Amouyal, Marc Sapoval, Anne Laure Pointet, Bruno Landi, Yosra Zaimi, Céline Lepère, Olivier Pellerin, Julien Taieb
INTRODUCTION: Hepatic arterial infusion (HAI) chemotherapy with oxaliplatin is an accepted option in the management of colorectal cancer (CRC) with dominant liver metastases (LM). However, despite prolonged control, some patients experience disease progression. On the other hand, oxaliplatin leads to dose-limiting toxicity. In these cases, the use of a second-line HAI with an alternative drug has never been reported to date. We evaluated treatment outcomes in patients receiving second-line HAI with 5-FU or mitomycin C, after first-line HAI of oxaliplatin in heavily pretreated patients...
December 7, 2017: Clinics and Research in Hepatology and Gastroenterology
https://www.readbyqxmd.com/read/29203965/the-preventive-effect-of-the-impaired-liver-function-for-antiemetic-therapy-against-chemotherapy-induced-nausea-and-vomiting-in-hepatocellular-carcinoma-patients
#4
Tomohiro Nishikawa, Akira Asai, Norio Okamoto, Hidetaka Yasuoka, Ken Nakamura, Keisuke Yokohama, Hideko Ohama, Yusuke Tsuchimoto, Shinya Fukunishi, Yasuhiro Tsuda, Kazuhiro Yamamoto, Kazuhide Higuchi
Transarterial chemoembolization and hepatic arterial infusion chemotherapy are recommended for the treatment in patients with intermediate stage of hepatocellular carcinoma. Impaired liver function was sometime observed in patients with hepatocellular carcinoma after transarterial chemoembolization or hepatic arterial infusion chemotherapy. However, what kinds of factors deeply influence in impaired liver function are not clear. A retrospective study was performed to evaluate the risk factors of impaired liver function in cisplatin-naïve patients treated with these therapies using cisplatin...
November 2017: Journal of Clinical Biochemistry and Nutrition
https://www.readbyqxmd.com/read/29181682/effectiveness-of-hepatic-artery-infusion-hai-versus-selective-internal-radiation-therapy-y90-for-pretreated-isolated-unresectable-colorectal-liver-metastases-iu-crclm
#5
Mashaal Dhir, Mazen S Zenati, Heather L Jones, David L Bartlett, M Haroon A Choudry, James F Pingpank, Matthew P Holtzman, Nathan Bahary, Melissa E Hogg, Herbert J Zeh, David A Geller, J Wallis Marsh, Allan Tsung, Amer H Zureikat
BACKGROUND: In the era of modern effective systemic chemotherapy, the comparative effectiveness of hepatic artery infusion (HAI) versus selective internal radiation therapy (yttrium-90 [Y90]) for pretreated patients with isolated unresectable colorectal liver metastasis (IU-CRCLM) remains unknown. This study sought to compare the overall survival (OS) after HAI versus Y90 for IU-CRCLM patients treated with modern chemotherapy and to perform a cost analysis of both regional methods. METHODS: This study retrospectively reviewed patients receiving HAI or Y90 in combination with modern chemotherapy as second-line therapy for IU-CRCLM...
November 27, 2017: Annals of Surgical Oncology
https://www.readbyqxmd.com/read/29165816/prospective-phase-ii-trial-of-combination-hepatic-artery-infusion-and-systemic-chemotherapy-for-unresectable-colorectal-liver-metastases-long-term-results-and-curative-potential
#6
Linda M Pak, Nancy E Kemeny, Marinela Capanu, Joanne F Chou, Taryn Boucher, Andrea Cercek, Vinod P Balachandran, T Peter Kingham, Peter J Allen, Ronald P DeMatteo, William R Jarnagin, Michael I D'Angelica
BACKGROUND/OBJECTIVES: Combination hepatic artery infusion (HAI) and systemic (SYS) chemotherapy for unresectable CRLM results in high tumor-response rates. This study represents an update of long-term survival and conversion to resectability in patients with unresectable CRLM treated with HAI and SYS chemotherapy in a phase II study. METHOD: The primary endpoint was complete resection. Multivariate and landmark analysis assessed the effect of complete resection on progression-free (PFS) and overall survival (OS)...
November 22, 2017: Journal of Surgical Oncology
https://www.readbyqxmd.com/read/29113660/functional-hepatic-imaging-as-a-biomarker-of-primary-and-secondary-tumor-response-to-loco-regional-therapies
#7
REVIEW
H L Lewis, M A Ghasabeh, P Khoshpouri, I R Kamel, T M Pawlik
Objective criteria to measure tumor response are a key tenet for assessment of treatment efficacy when evaluating a therapeutic modality. Several response criteria have been proposed including the Response Evaluation Criteria in Solid Tumors (RECIST), modified RECIST (mRECIST), RECIST 1-1, and European Association for the Study of the Liver (EASL) guidelines. Response following loco-regional therapies (LRT) can be particularly difficult to assess as post-treatment changes may not always relate to changes in lesion size...
December 2017: Surgical Oncology
https://www.readbyqxmd.com/read/29108373/conditional-survival-estimate-in-patients-with-barcelona-clinic-liver-cancer-stage-b-c-hepatocellular-carcinoma-treated-with-hepatic-arterial-infusion-chemotherapy-with-without-concurrent-radiotherapy
#8
In Rae Cho, Hye Won Lee, Ki Jun Song, Beom Kyung Kim, Seung Up Kim, Do Young Kim, Sang Hoon Ahn, Jinsil Seong, Kwang-Hyub Han, Jun Yong Park
Conditional survival (CS) provides a prognosis of patients who have already survived several years after treatment. We investigated CS in Barcelona Clinic Liver Cancer (BCLC) stage B/C hepatocellular carcinoma (HCC) patients treated with hepatic arterial infusion chemotherapy (HAIC) with or without concurrent radiotherapy (CRT). A total of 181 patients diagnosed with HCC who were treated with HAIC with or without CRT between 2011 and 2015 were retrospectively reviewed. Overall survival (OS) and CS were calculated and a subgroup analysis was performed...
October 3, 2017: Oncotarget
https://www.readbyqxmd.com/read/29082453/rapidly-growing-hepatocellular-carcinoma-after-direct-acting-antiviral-treatment-of-chronic-hepatitis-c
#9
Toshihiro Kawaguchi, Tatsuya Ide, Hironori Koga, Reiichiro Kondo, Ichiro Miyajima, Teruko Arinaga-Hino, Reiichiro Kuwahara, Keisuke Amano, Takashi Niizeki, Masahito Nakano, Ryoko Kuromatsu, Takuji Torimura
We report on a 62-year-old man with chronic hepatitis C who developed rapidly growing hepatocellular carcinoma (HCC) after achieving sustained virological response at post-treatment week 24 (SVR 24) by direct-acting antiviral (DAA) treatment. In 2008, he failed interferon therapy at 56 years of age. He received daclatasvir plus asunaprevir for 24 weeks after confirmation of no liver tumor by abdominal ultrasonography. He had no advanced liver fibrosis. Three months after initiation of DAA treatment, a liver tumor measuring 6 mm in diameter was detected by ultrasonography and confirmed with magnetic resonance imaging...
October 29, 2017: Clinical Journal of Gastroenterology
https://www.readbyqxmd.com/read/29074347/management-consensus-guideline-for-hepatocellular-carcinoma-2016-updated-by-the-taiwan-liver-cancer-association-and-the-gastroenterological-society-of-taiwan
#10
(no author information available yet)
BACKGROUND: Hepatocellular carcinoma (HCC) is one of the leading causes of cancer-related mortality in Taiwan. To help clinical physicians to manage patients with HCC, the Taiwan Liver Cancer Association and the Gastroenterological Society of Taiwan produced the management consensus guideline for HCC. METHODS: The recommendations focus on nine important issues on management of HCC, including surveillance, diagnosis, staging, surgery, local ablation, transarterial chemoembolization/transarterial radioembolization/hepatic arterial infusion chemotherapy, systemic therapy, radiotherapy, and prevention...
October 23, 2017: Journal of the Formosan Medical Association, Taiwan Yi Zhi
https://www.readbyqxmd.com/read/29063296/surgical-resection-does-not-improve-survival-in-multifocal-intrahepatic-cholangiocarcinoma-a-comparison-of-surgical-resection-with-intra-arterial-therapies
#11
G Paul Wright, Samantha Perkins, Heather Jones, Amer H Zureikat, J Wallis Marsh, Matthew P Holtzman, Herbert J Zeh, David L Bartlett, James F Pingpank
BACKGROUND: Multifocal intrahepatic cholangiocarcinoma (ICC) has traditionally been treated with surgical resection when amenable. Intra-arterial therapy (IAT) for multifocal ICC has not been directly compared with surgical resection. METHODS: A single-center, retrospective review of consecutive patients treated for multifocal ICC was conducted. Patients with distant metastases or treatment with systemic chemotherapy alone were excluded. Patients were divided into two groups: surgical resection versus IAT; IAT included transarterial chemoembolization (TACE), transarterial radioembolization (TARE), and hepatic arterial infusion (HAI) pump therapy...
October 23, 2017: Annals of Surgical Oncology
https://www.readbyqxmd.com/read/29061175/hepatic-artery-infusion-chemotherapy-using-mfolfox-versus-transarterial-chemoembolization-for-massive-unresectable-hepatocellular-carcinoma-a-prospective-non-randomized-study
#12
Min-Ke He, Yong Le, Qi-Jiong Li, Zi-Shan Yu, Shao-Hua Li, Wei Wei, Rong-Ping Guo, Ming Shi
BACKGROUND: Transarterial chemoembolization (TACE) is recommended as the standard care for unresectable hepatocellular carcinoma (HCC) at Barcelona Clinic Liver Cancer (BCLC) stage A-B. However, the efficacy of TACE on large (≥ 10 cm) stage A-B HCC is far from satisfactory, and it is proposed that hepatic artery infusion chemotherapy (HAIC) might be a better first-line treatment of this disease. Hence, we compared the safety and efficacy of HAIC with the modified FOLFOX (mFOLFOX) regimen and those of TACE in patients with massive unresectable HCC...
October 23, 2017: Chinese Journal of Cancer
https://www.readbyqxmd.com/read/28930817/cronkhite-canada-syndrome-associated-with-colon-cancer-metastatic-to-liver-a-case-report
#13
Jing Wang, Lei Zhao, Nina Ma, Juanjuan Che, Huihui Li, Bangwei Cao
RATIONALE: Cronkhite-Canada Syndrome (CCS) is an idiopathic, nonhereditary syndrome haracterized by gastrointestinal (GI) polyposis and ectodermal changes including alopecia, onychatrophia, and pigmentation. CCS colon polyps were previously considered to be benign neoplasms. However, serrated adenoma was reported to be associated with malignant neoplasms in some cases of gastric and colorectal carcinomas, and esophageal cancers. Although malignant colon and gastric cancer have been reported in CCS, reports of distant metastasis have been rare in CCS...
September 2017: Medicine (Baltimore)
https://www.readbyqxmd.com/read/28882769/adjuvant-hepatic-artery-infusion-chemotherapy-after-hemihepatectomy-for-gastric-cancer-liver-metastases
#14
Yasuyuki Fukami, Yuji Kaneoka, Atsuyuki Maeda, Yuichi Takayama, Takamasa Takahashi, Masahito Uji, Takashi Kumada
BACKGROUND: The most frequent pattern of recurrence is remnant liver after hepatectomy for gastric cancer liver metastases (GLM). The evidence of adjuvant hepatic artery infusion chemotherapy (HAIC) after hepatectomy for GLM is lacking. The aim of this study was to evaluate the efficacy of adjuvant HAIC after hemihepatectomy for GLM. METHODS: Between 2001 and 2012, 14 patients who underwent hemihepatectomy for GLM were included in this study. Adjuvant HAIC to the remnant hemiliver was the FEM regimen (333 mg/m(2) 5-fluorouracil each week, 30 mg/m(2) epirubicin once every 4 weeks, and 2...
October 2017: International Journal of Surgery
https://www.readbyqxmd.com/read/28871990/transarterial-radioembolization-versus-concurrent-chemoradiation-therapy-for-locally-advanced-hepatocellular-carcinoma-a%C3%A2-propensity-score-matching-analysis
#15
COMPARATIVE STUDY
Jeong Eun Song, Kyu Sik Jung, Do Young Kim, Kijun Song, Jong Yun Won, Hye Won Lee, Beom Kyung Kim, Seung Up Kim, Jun Yong Park, Sang Hoon Ahn, Jinsil Seong, Kwang-Hyub Han
PURPOSE: It is unclear whether the efficacy and safety of concurrent chemoradiation therapy (CCRT) and transarterial radioembolization (TARE) with (90)Y are comparable in patients with locally advanced hepatocellular carcinoma. METHODS AND MATERIALS: In total, 209 treatment-naive patients with stage B or C cancer according to the Barcelona Clinic Liver Cancer classification who were treated with TARE or CCRT were analyzed. Propensity scores were calculated and matched at a 1:1 ratio for TARE versus CCRT using age, tumor size, tumor number, portal vein thrombosis, and Barcelona Clinic Liver Cancer staging...
October 1, 2017: International Journal of Radiation Oncology, Biology, Physics
https://www.readbyqxmd.com/read/28829195/how-and-when-adjuvant-treatment-should-be-intensified-in-stage-iii-colorectal-cancers
#16
Khalil Saleh, Nadine Khalife-Saleh, Hampig Raphael Kourie, Georges Chahine
The adjuvant chemotherapy (FOLFOX) represents the standard of care in stage III colon cancer with some exceptions in old patients. Adjuvant treatment must also be discussed in high-risk stage II colon cancer. However, 40-50% of patients develop disease recurrence after curative R0 surgical resection. The liver was the most common site of recurrence followed by peritoneum. Although adjuvant chemotherapy improved disease-free survival and overall survival, 5-year overall survival remains less than 55% in stage III colon cancer...
August 22, 2017: Future Oncology
https://www.readbyqxmd.com/read/28810886/factors-affecting-survival-after-concurrent-chemoradiation-therapy-for-advanced-hepatocellular-carcinoma-a-retrospective-study
#17
Ja Kyung Kim, Jun Won Kim, Ik Jae Lee, Seung-Moon Joo, Kwang-Hun Lee, Eun-Suk Cho, Jeong-Sik Yu, Tae Joo Jeon, Yonsoo Kim, Jung Il Lee, Kwan Sik Lee
BACKGROUND: Concurrent chemoradiation therapy (CCRT) followed by hepatic arterial infusional chemotherapy (HAIC) was reported to be effective for advanced hepatocellular carcinoma (HCC) with portal vein thrombosis. However, transarterial chemoembolization (TACE) is not preferred in this setting. The aim of this study was to assess the factors affecting survival after CCRT, including additional TACE during repeated HAIC. METHODS: Thirty-eight patients who underwent CCRT as the initial treatment for Barcelona Clinic Liver Cancer stage C HCC with vascular invasion between 2009 and 2016 were reviewed retrospectively...
August 15, 2017: Radiation Oncology
https://www.readbyqxmd.com/read/28728985/adjuvant-hepatic-arterial-infusion-chemotherapy-is-beneficial-for-selective-patients-with-hepatocellular-carcinoma-undergoing-surgical-treatment
#18
Jui-Hu Hsiao, Cheng-Chung Tsai, Tsung-Jung Liang, Chia-Ling Chiang, Huei-Lung Liang, I-Shu Chen, Yu-Chia Chen, Po-Ming Chang, Nan-Hua Chou, Being-Whey Wang
BACKGROUND: Recurrence rate after curative surgical resection of Hepatocellular carcinoma (HCC) remains high. Postoperative hepatic arterial infusion chemotherapy (HAIC) has been suggested to improve survival. This study is to investigate the efficacy of HAIC in the patients with poor tumor factors such as vascular invasion or multiplicity. METHODS: From 2006 to 2014, 221 patients with HCC undergoing hepatectomy and pathologically staged as ≧ T2 (American Joint Committee on Cancer TNM staging system, 7th edition) were included...
July 17, 2017: International Journal of Surgery
https://www.readbyqxmd.com/read/28705491/proposal-of-selection-criteria-for-operative-resection-of-hepatocellular-carcinoma-with-inferior-vena-cava-tumor-thrombus-incorporating-hepatic-arterial-infusion-chemotherapy
#19
Yosuke Kasai, Etsuro Hatano, Satoru Seo, Kojiro Taura, Kentaro Yasuchika, Hideaki Okajima, Toshimi Kaido, Shinji Uemoto
BACKGROUND: Because operative resection of hepatocellular carcinoma with inferior vena cava tumor thrombus has been associated with a substantial risk of recurrence and postoperative morbidity, adequate patient selection for resection is necessary. Our aim was to propose selection criteria for resection of hepatocellular carcinoma with inferior vena cava tumor thrombus. METHODS: Long-term outcomes were analyzed retrospectively in 39 operative cases of hepatocellular carcinoma with inferior vena cava tumor thrombus (1996-2015)...
October 2017: Surgery
https://www.readbyqxmd.com/read/28685137/effect-of-double-platinum-agents-combination-of-miriplatin-transarterial-oily-chemoembolization-and-cisplatin-hepatic-arterial-infusion-chemotherapy-in-patients-with-hepatocellular-carcinoma-report-of-two-cases
#20
Kohei Ogawa, Kenya Kamimura, Yukari Watanabe, Yosuke Motai, Daisuke Kumaki, Ryoya Seki, Akira Sakamaki, Satoshi Abe, Hirokazu Kawai, Takeshi Suda, Satoshi Yamagiwa, Shuji Terai
Hepatocellular carcinoma (HCC) is one of the most common cancers and the third highest cause of cancer-associated mortality worldwide. The treatment of HCC is complicated by its variable biological behavior and the frequent coexistence of chronic liver disease, particularly cirrhosis. To date, multiple treatment modalities have been developed according to the stage of the tumor and the hepatic functional reserve, including transarterial treatments such as transarterial chemoembolization, transarterial oily chemoembolization (TOCE), and hepatic arterial infusion chemotherapy (HAIC)...
June 16, 2017: World Journal of Clinical Cases
keyword
keyword
84585
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"